The different efficacy of therapies in chronic hepatitis B (CHB) and in CHD could explain this paradox; the only available therapy for CHD has remained interferon-alpha (IFN-α), which failed to control HDV infection in a significant proportion of patients, while over 90% of CHB cases have not progressed to terminal disease thanks to the effective antivirals used in the last 20 years. This evidence concerns the gene IFNA1 and coronary artery disorder.